Pierre Gantner, Christine Koeppel, Marialuisa Partisani, Marie-Laure Batard, Claudine Bernard-Henry, Christine Cheneau, Erik De Mautort, Michele Priester, Patrice Muret, Charlotte Sueur, Samira Fafi-Kremer, David Rey
BACKGROUND: To decrease drug burden among HIV-1-positive adults, we need a new gold standard for antiretroviral therapy maintenance strategies. METHODS: This retrospective study aimed to assess efficacy in maintenance strategy of atazanavir (ATV) and raltegravir (RAL) dual therapy. The proportion of patients with HIV-1 RNA < 40 copies/ml at specific time points was recorded. Immunological response, safety, and pharmacokinetics were assessed. RESULTS: Overall, 39 patients were switched to a RAL/ATV (n = 32) or RAL/ATV plus ritonavir (n = 7) regimen...
December 2014: Scandinavian Journal of Infectious Diseases